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The role ofgenetic mutationsinthe developmentofosteosarcoma,such asalterationsinp53 andRb, is well understood. However,
the signiﬁcance of epigenetic mechanisms in the progression of osteosarcoma remains unclear and is increasingly being inves-
tigated. Recent evidence suggests that epigenetic alterations such as methylation and histone modiﬁcations of genes involved in
cell cycle regulation and apoptosis may contribute to the pathogenesis of this tumor. Importantly, understanding the molecular
mechanisms of regulation of these pathways may give insight into novel therapeutic strategies for patients with osteosarcoma.
This paper serves to summarize the described epigenetic mechanisms in the tumorigenesis of osteosarcoma, speciﬁcally those
pertaining to apoptosis and cell cycle regulation.
1.Introduction
Osteosarcoma is the most common primary malignant tu-
mor of the bone in children and adolescents. As a result of
recent advances in chemotherapy, long-term survival rates
for osteosarcoma patients with no detectable metastases at
diagnosis have improved dramatically. However, for patients
that present with metastasis or have disease recurrence, the
long-term survival rate is less than 20% [1–3]. Therefore,
there is an ongoing need to understand the biology of
osteosarcoma progression and metastasis in order to identify
new therapeutic approaches.
Numerous studies have investigated the pathogenesis of
osteosarcoma. This tumorhas generally been associated with
alterations in genes involved in cell cycle regulation and
apoptosis. Most notably, the p53 and retinoblastoma protein
(Rb) pathways have been shown to play a role in the pro-
gression of osteosarcoma [4–7]. However, much of the focus
has been on understanding point mutations or deletions,
disregarding any potential role of epigenetic mechanisms in
the inactivation of these and other important pathways.
Epigenetics involves changes in the activation of genes
without altering the basic structure of DNA. This includes
but is not limited to CpG island methylation within gene
promoter regions and acetylation, deacetylation, and/or
methylation of histone proteins [8, 9]. Epigenetic regulation
has been considered a mechanism for the inactivation of
tumor suppressor pathways in several types of cancer. These
changes can impact gene expression, but how this may
contribute to the process of tumorigenesis requires further
investigation.
Recent advances in the study of the role of epigenetics in
the progression of osteosarcoma have increased the under-
standing of the pathogenesis of this disease, an area which
is complex and not well deﬁned. Altering gene expression
and the signaling pathways that control the cell cycle and
apoptosis can contribute to the tumorigenic process and cell
transformation from a normal to a malignant phenotype.
This paper serves to review what is currently known about
the eﬀects of aberrant methylation and other epigenetic
mechanisms on the regulation of cell cycle and apoptosis in
osteosarcoma.2 Sarcoma
2.RbPathway
Retinoblastoma protein (Rb) is a tumor suppressor protein
that is inactivated in several types of cancer [10]. It has
been shown to play a role in cell cycle control by inhibiting
entry into the S-phase, thus creating a G1 checkpoint [11,
12]. About 70% of human primary osteosarcoma tumors
have molecular aberrations in the Rb gene. The most
common alterations include genetic deletions, mutations,
andstructuralrearrangements[1,13–15].Whileinactivation
by hypermethylation of the Rb gene has been shown to
contribute to pathogenesis of other tumor types such as ret-
inoblastoma [16], analysis of patient samples has suggested
that this inactivation may not play an essential role in the
progression of osteosarcoma. In one study, only 6 of 76
patients displayed heterozygous Rb methylation and 6 out
of 41 patients displayed Rb promoter methylation. It is im-
portant to note, however, that loss of the Rb gene was only
detectable in 37.2% of these patients, which is considerably
lower than previously reported data [17]. Therefore, further
analysis of Rb methylation in osteosarcoma is warranted.
It has been shown that Rb-dependent G1 arrest involves
p16INK4A inhibition of cyclin D/cdk4 and cyclin D/cdk6
complexes, which normally initiate the phosphorylation of
Rb [18]. Therefore, alterations in Rb, cyclin D, cdk4/6, or
p16INK4A may result in a loss of the G1 checkpoint,leading to
the accumulation of genetic damage which may contribute
to tumor development (Figure 1). Until recently, epigenetic
modiﬁcations of the p16INK4A gene, a tumor suppressor that
is often altered in osteosarcoma cell lines [19], were not
investigated. In a study with p16-negative osteosarcoma
samples, 8/15 had total or partial CpG methylation of the
p16INK4A promoter and 6/15 were pRb-negative [20]. Over-
all, these data suggest that in addition to other mechanisms
ofRb pathway inhibition, promotermethylation ofeitherRb
or p16INK4A may play a role in the disruption of cell cycle
control, promoting the developmentof osteosarcoma.
3.p53Pathway
The p53 gene (TP53) is known as the most commonly
mutated gene in human cancers [1, 21–23]. P53 plays an
important role in the regulation of apoptosis, cell cycle
arrest, and DNA repair. When DNA damage occurs, p53
upregulates WAF/CIP resulting in increased p21 protein.
P21 can then bind to and inhibit G1-S/CDK and S/CDK
complexes to arrest cell division. If damage is irreparable,
activated p53 can directly regulate the expression of apop-
totic genes, resulting in the initiation of apoptosis [23]. The
frequency of p53 alterations in osteosarcoma ranges from
∼30% point mutations to ∼80% allelic loss, suggesting that
p53 status plays an important role in the tumorigenesis
of osteosarcoma [1]. However, few groups have investi-
gated the role of epigenetic regulation of p53 pathways in
osteosarcoma. Recently a novel protein, hypermethylated in
cancer (HIC1), was identiﬁed to modulate p53-dependent
apoptosis (Figure 1). Inactivation of HIC1 results in the
upregulation of SIRT1 deacetylase which then deacetylates
and inactivates p53. This results in the circumvention of
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Figure 1: Schematic model of epigenetic events that regulate cell
cycle progressioninosteosarcoma.Thecell cycleregulators Rb, p53,
p16INK4A,p14 ARF, andHIC1 havebeen foundto behypermethylated
a tt h eg e n ep r o m o t e ri no s t e o s a r c o m a( ∗). These alterations may
contribute to dysregulation of cell cycle control (loss of the G1
checkpoint) and may promote tumor development.
apoptosis and then cells are able to survive DNA damage,
a process that may promote tumor development [24]. In
order to investigate the mechanism for loss of function of
HIC1 and p53 in osteosarcoma, Chen et al. analyzed the
regulation of HIC1 in tumors of HIC1+/− p53+/− mice.
Eight of 13 osteosarcomas demonstrated HIC1 1b promoter
hypermethylation and 2/13 had hypermethylation of the
HIC11a promoter. Bothalterations were associated with loss
of HIC1 expression, whereas tumors with abundant HIC1
expression had no apparent hypermethylation of the HIC1
promoter. Inaddition,2/4osteosarcomas inp53+/− micehad
abundant HIC1 1b hypermethylation. This suggests that loss
of HIC1 function resulting from promoter hypermethyla-
tion, along with inactivation of p53, is associated with the
development of osteosarcoma. To further examine whether
HIC1 promoter hypermethylation with p53 inactivation was
important in the development of human osteosarcomas,
Chen et al. analyzed 44 osteosarcoma patient samples. It was
demonstrated that 8/21 (38%) tumors with p53 mutations
and 2/23 (9%) without p53 mutations were characterized
by HIC1 promoter hypermethylation [25]. In addition, it
has been found that 17% of pediatric osteosarcomas display
hypermethylation of the HIC1 promoter [26]. This further
validates that in addition to mutation or deletion of the
p53 gene, regulation of the p53 pathway by HIC1 promoter
hypermethylation resulting in p53 inactivation also plays an
important role in the development of osteosarcoma.
4.p14ARF/CDKN2A
The p14ARF protein, which is encoded by the CDKN2Agene,
is critical in the regulation of cell cycle control (Figure 1).
P14ARF regulatesp53functionbyinhibitingMDM2,allowing
p53 to upregulate p21 expression. P21 can then bind to and
inactivate cyclin/CDKcomplexes, resulting in G1 arrest [27].Sarcoma 3
In an examination of tissue samples from 59 osteosarcoma
patients, it was demonstrated that epigenetic alterations in
p14ARF correlated with poor prognosis. Using methylation-
speciﬁc polymerase chain reaction (PCR), it was shown
that 15/32 (47%) osteosarcomas had aberrant methylation
of the p14ARF gene (CDKN2A) promoter. As anticipated,
these 15 osteosarcomas with methylated p14ARF showed
negative or weak expression of the p14ARF protein. This
conﬁrms that methylation of the p14ARF gene promoter is
associated with loss of protein expression. Methylation did
not correlate with age, gender, location of tumor, tumor
volume, stage, histologic subtype, or chemotherapeutic re-
sponse. Interestingly, the patients with p14ARF methylation
hadalowermediansurvivalthanthepatientswithoutp14ARF
methylation, which was statistically signiﬁcant according to
Kaplan-Meier’s survival analysis. This suggests that aberrant
p14ARF promoter methylation correlates with poor survival
in patients with osteosarcoma. In addition, 9/14 patients
with p14ARF promoter methylation developed metastases.
Associated deaths correlated with the incidence of metastasis
but were not signiﬁcant due to the size of the cohort [28].
Overall,thesedatasuggestthatp14ARF promotermethylation
mayresultinthelossofp53-dependentG1arrest, which may
promote tumor development. However, further study into
the signiﬁcance of p14ARF promoter methylation in primary
osteosarcoma and metastasis is warranted and may provide
further insight into the importance of p14ARF methylation in
osteosarcoma progression.
5.RASSF1A
Ras association domain family 1A (RASSF1A) is a newly
identiﬁed tumor suppressor gene that is involved in path-
ways regulating cell cycle arrest and apoptosis. Although
unclear, RASSF1A has been identiﬁed to be involved in
death receptor-dependent apoptosis [29]. RASSF1A has
been demonstrated to be silenced in cancers of the ovary,
nasopharynx, kidney, stomach, prostate, urinary bladd-
er, thyroid, and neuroblastoma [30–37]. The method of
RASSF1A silencing in all of these tumor types was deter-
mined to be a result of aberrant methylation of the RASSF1A
promoter. Recently, RASSF1 was also shown to be a tumor
suppressor in osteosarcoma. Lim et al. investigated the ex-
pression of RASSF1A in primary osteosarcomas and cell
lines and demonstrated a lack of RASSF1A expression in
4/10 primary and 5/6 cell lines. Upon treatment of these
RASSF1A-negative cell lines with the demethylating agent 5-
aza-2 -deoxycytidine, RASFF1A expression was upregulated.
This suggests that RASSF1A promoter methylation may
be a possible mechanism for the transcriptional silencing
of RASSF1A. In contrast with these results, Lim et al.
found that several primary osteosarcomas and one cell line
(SAOS-2) did not display methylation of the RASSF1A
promoter [38]. Therefore, further studies incorporating a
greater number of osteosarcoma samples and cell lines are
warranted. Additionally, Hou et al. performed a thorough
analysis of promoter hypermethylation of a wide of array
of genes in osteosarcoma and normal tissues using Q-MSP
analysis. RASSF1A promoter hypermethylation was present
in 14.29% (mean) of tumor tissues and in 1.29% (mean)
of normal tissues, demonstrating that promoter methylation
is a method of RASSF1A silencing in osteosarcoma [39].
This validatesthatlossofRASSF1Abypromotermethylation
may play a role in the development of osteosarcoma by
dysregulation of cell cycle control and apoptosis.
6.M o n o m e th ylH i s t o n eH 3L y s i n e27
Several groups have demonstrated the various histone mod-
iﬁcations that occurduring apoptosis, termed the “apoptotic
histone mark” [40]. Histone tails are known to be posttrans-
lationally modiﬁed by acetylation, methylation, phosphory-
lation and ubiquitination of lysine, and/or arginine residues
[41, 42]. One such modiﬁcation, methylation of lysine 27
in histone H3, was associated with gene repression and has
been implicated in tumorigenesis [43–45]. In osteosarcoma
cells, induction of lysine 27 methylation in histone H3 has
been associated with caspase-dependent apoptosis and cell
cycle arrest, suggesting that this epigenetic mark may play
a possible role in these processes [46]. Conversely, osteosar-
coma cells undergoing apoptosis displayed elevated levels of
monomethylated histone H3 lysine 27 [47]. These studies
are the ﬁrst to provide evidence that epigenetic modiﬁcation
of histone H3 by lysine 27 methylation may be linked with
apoptosis in osteosarcoma. Although a correlative study, this
ﬁnding suggests a possible role for histone modiﬁcations in
the induction of apoptosis in osteosarcoma.
7.Discussion
Osteosarcoma is a relatively rare disease, accounting for
about 5% of all pediatric cancers. However, more than 30%
of patients with osteosarcoma die of pulmonary metas-
tasis within 5 years after diagnosis [48]. While adjuvant
chemotherapy has improved overall survival rates compared
to surgery alone, the fatality rates have remained unchanged
for more than 20 years. Therefore, there is an ongoing
need for new therapeutic strategies and a more thorough
understanding of the genetic and molecular mechanisms
that participate in the development of osteosarcoma and
in the metastatic process, particularly to the lung. Multiple
pathways have been implicated in the pathogenesis of oste-
osarcoma. Speciﬁcally, pathways involving cell cycle and
apoptosis have been found to play a role in tumorigenesis.
While there is abundant evidence that pathways involving
p53, Rb, and many key mediators of cell cycle regulation
and apoptosis contribute to osteosarcoma, how these critical
genes are altered is not clearly understood. Recent advances
in the study of epigenetics have shown that these pathways
may be regulated by methylation, histone modiﬁcations,
and other epigenetic mechanisms. This paper highlights the
importance of these epigenetic events in the development of
osteosarcoma, speciﬁcally pertaining to cell cycle regulation
and apoptosis. Overall, a growing body of evidence suggests
that use of therapeutic agents that target epigenetic mecha-
nisms may be beneﬁcial for patients with osteosarcoma.4 Sarcoma
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